COVERAGE CONFIRMATION!

Effective March 2024, ADSTILADRIN® (nadofaragene firadenovec-vncg) was placed on The Veterans Affairs National Formulary (VANF).

This is great news for our Veterans living with High-Risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS) with or without papillary tumors.

The Veterans Health Administration (VHA) is America's largest integrated healthcare system, providing care at 1,321 health care facilities, including 172 medical centers and 1,138 outpatient sites of care of varying complexity (VHA outpatient clinics), serving 9 million enrolled Veterans each year.[1]

ADSTILADRIN's VANF details:

- ADSTILADRIN is on the VANF
- A Prior Authorization (PA) is required
- Care is provided by a Veterans Affairs (VA)/VA Community Care urology provider or in consultation with a VA urology provider
- Criteria for use (CFU) are in place for ADSTILADRIN[2]
- ADSTILADRIN is listed on the VA Clinical Pathways[3]
  - Clinical Pathways standardize evidence-based practices to ensure high-quality, cost-effective care for Veterans at each point in their care plan

Best practices for ordering ADSTILADRIN at the VA

Confirm that your site has an active account with Besse Medical, Amerisource Bergen Specialty (ASD) or Frontier Therapies

- Sites with an active Besse Medical or Frontier Therapies account
  - Proceed to order at your convenience
- Sites without an active Besse Medical or Frontier Therapies account
  - An active ASD account will be linked to Besse Medical by contacting Ferring. To facilitate the process, please email Rocco Montesano at rocco.montesano@ferring.com with a copy to Ferring Trade Customer Support at US1customerrelations@ferring.com.
- Ferring partners with Besse Medical and Frontier Therapies as our specialty distributor network
  - The vendor relationship is with the specialty distributor; therefore, no additional contracts are needed between the VA site and Ferring. Ferring is the manufacturer

Order ADSTILADRIN

To learn more about ADSTILADRIN's specialty distribution or ordering, please reach out to **Associate Director of Trade, Rocco Montesano, at rocco.montesano@ferring.com**

Please see Important Safety Information on page 2 and full Prescribing Information at adstiladrinHCP.com.

Indication and Important Safety Information

INDICATION

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.

WARNINGS AND PRECAUTIONS

- ***Risk with delayed cystectomy:*** Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
- ***Risk of disseminated adenovirus infection:*** Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

Please click here for full Prescribing Information.

References: 1. Veterans Affairs. Veterans Health Administration. Accessed April 19, 2024. https://www.va.gov/health/ **2.** Veterans Affairs. Nadofaragene firadenovec-vncg (ADSTILADRIN) criteria for use September 2023 VA pharmacy benefits management services, medical advisory panel. Accessed April 19, 2024. https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Nadofaragene_firadenovec_ADSTILADRIN_Criteria_Sep_2023.pdf **3.** Veterans Affairs. Clinical pathways. Accessed April 19, 2024. https://www.cancer.va.gov/CANCER/clinical-pathways.html